Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023

Published on : Published by : BioBuzz Media

Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023 By Alex Keown and Sarah EllinwoodMay 19, 2023 Funding, Awards and Collaborations PQE Group US Earns 2023 Great [….]

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov

Published on : Published by : BioBuzz Media

CEL-SCI Corporation (NYSE American: CVM) announced today that the results of its 10-year IT-MATTERS pivotal Phase 3 clinical trial in head and neck cancer with its investigational immunotherapy Multikine®* (Leukocyte Interleukin, Injection) have been posted on clinicaltrials.gov per U.S. government requirements.